- Home
- BGI vs FGEN Comparison
BGI vs FGEN Comparison
Compare BGI & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- FGEN
- Stock Information
- Founded
- BGI 1879
- FGEN 1993
- Country
- BGI Canada
- FGEN United States
- Employees
- BGI N/A
- FGEN N/A
- Industry
- BGI
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- FGEN Health Care
- Exchange
- BGI Nasdaq
- FGEN Nasdaq
- Market Cap
- BGI 31.1M
- FGEN 34.5M
- IPO Year
- BGI 2005
- FGEN 2014
- Fundamental
- Price
- BGI $1.60
- FGEN $0.40
- Analyst Decision
- BGI
- FGEN
- Analyst Count
- BGI 0
- FGEN 0
- Target Price
- BGI N/A
- FGEN N/A
- AVG Volume (30 Days)
- BGI 15.5K
- FGEN 996.1K
- Earning Date
- BGI 12-31-2024
- FGEN 11-12-2024
- Dividend Yield
- BGI N/A
- FGEN N/A
- EPS Growth
- BGI N/A
- FGEN N/A
- EPS
- BGI N/A
- FGEN N/A
- Revenue
- BGI $131,596,264.00
- FGEN $180,015,000.00
- Revenue This Year
- BGI N/A
- FGEN $19.67
- Revenue Next Year
- BGI N/A
- FGEN N/A
- P/E Ratio
- BGI N/A
- FGEN N/A
- Revenue Growth
- BGI 4.01
- FGEN 16.15
- 52 Week Low
- BGI $1.46
- FGEN $0.18
- 52 Week High
- BGI $4.88
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- BGI 37.69
- FGEN 58.65
- Support Level
- BGI $1.58
- FGEN $0.34
- Resistance Level
- BGI $1.67
- FGEN $0.37
- Average True Range (ATR)
- BGI 0.09
- FGEN 0.04
- MACD
- BGI 0.02
- FGEN -0.00
- Stochastic Oscillator
- BGI 33.31
- FGEN 76.07
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.